Table 2.
Compound | GI50 (µM) | ||||||
---|---|---|---|---|---|---|---|
MCF-7 | NCI-H460 | A375-C5 | HeLa | 786-O | Caki-2 | AGS | |
TXA1 | 6.1 ± 0.4 # | 6.0 ± 0.3 # | 3.6 ± 1.2 # | 6.8 ± 0.5 | 8.1 ± 1.8 | 11.5 ± 1.8 | 35.3 ± 2.3 |
TXA1·HCl | 7.8 ± 0.9 | 6.9 ± 1.3 | 3.8 ± 0.8 | 6.4 ± 0.6 | 9.0 ± 1.1 | 9.3 ± 0.8 | 9.7 ± 0.2 |
Values presented refer to the mean ± SEM of at least three independent experiments. The maximum vehicles (DMSO for TXA1 and H2O for TXA1·HCl) concentration used was 0.25% and did not interfere with cell growth (data not shown). Doxorubicin was used as a positive control [GI50 concentrations: 65 ± 8.5 nM in MCF-7, 64 ± 6.8 nM in NCI-H460, 145 ± 9.8 nM in A375-C5, 20.7 ± 0.8 nM in HeLa, 135 ± 6.2 nM in 786-O, 152.3 nM in Caki-2 (from two experiments only), 90 ± 5 nM in AGS]. # data also included in Table 1 as the GI50 concentration of compound 1.